- The Institutional Review Board (IRB) has approved Aurora Spine’s multicentre study of its ZIP Interspinous Fixation Device
- The device is being developed for patients suffering from back pain due to symptomatic degenerative disc disease
- The study will involve 100 patients and Aurora Spine expects to see results within the year
- Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies
- Aurora Spine (ASG) closed out the day at C$0.81 per share
The Institutional Review Board (IRB) has approved Aurora Spine’s multicentre study of its ZIP Interspinous Fixation Device.
The device is being developed for patients suffering from back pain due to symptomatic degenerative disc disease.
Aurora Spine has partnered with Celéri Health, a real-world evidence company whose mission is to use patient-centric data to develop Real World Outcomes to accelerate drug and device discovery.
Trent Northcutt, Aurora’s president, CEO, and co-founder, commented,
“We have established a great relationship with Celéri Health for the data portion of our project using their Real World Outcomes platform,” he said.
Vipul Mangal, M.D., an interventional pain specialist from National Spine & Pain Centers, has adopted this therapy in his patients as a minimally invasive alternative approach.
Dr. Mangal commented,
“This device has been revolutionary in my practice as a minimally invasive device to significantly improve function and pain for my patients with back pain.”
Michael A. Fishman, MD, MBA., Director of Research at the Center for Interventional Pain & Spine in Lancaster, PA, also commented on the study.
“This multicenter study will involve 100 patients with results expected this year. The study is designed to demonstrate reproducible outcomes in the real-world with attention to pain, function, and quality of life,” he said.
The IRB is an FDA-registered constituted group that has been formally designated to review and monitor biomedical research involving human subjects.
Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
Aurora Spine (ASG) closed out the day at C$0.81 per share.
